|
AMP945 International Nonproprietary Name Narmafotinib
|
21 June 2023 at 8:55am
|
|
Amplia AGM to be held Thursday 24 August 2023
|
19 June 2023 at 5:55pm
|
|
Key to Corporate Governance Disclosures
|
31 May 2023 at 8:35am
|
|
2023 Corporate Governance Statement
|
30 May 2023 at 5:40pm
|
|
Annual Report to Shareholders
|
30 May 2023 at 5:40pm
|
|
AMP945 and FOLFIRINOX active in model of Pancreatic Cancer
|
29 May 2023 at 9:05am
|
|
Grant to collaborate with CSIRO Supplementary Announcement
|
23 May 2023 at 11:50am
|
|
Amplia receives grant to collaborate with CSIRO
|
22 May 2023 at 8:45am
|
|
ACCENT Trial Recruitment Progress
|
9 May 2023 at 12:05pm
|
|
Quarterly Activities and Cashflow Reports - March 23 Qtr
|
26 April 2023 at 10:30am
|
|
First Patient Recruited to Cohort 3 of ACCENT Trial
|
19 April 2023 at 8:50am
|
|
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
|
11 April 2023 at 12:45pm
|
|
ACCENT Trial Recruitment Progress
|
28 February 2023 at 11:55am
|
|
ATX - US Conference Presentation
|
23 February 2023 at 5:20pm
|
|
AmpliaTherapeutics - Lorne Cancer Conference Presentation
|
9 February 2023 at 8:40am
|
|
First Patient Recruited to Cohort 2 of Accent Trial
|
1 February 2023 at 11:50am
|
|
Quarterly Activities and Cashflow Reports - December 2022
|
30 January 2023 at 10:35am
|
|
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
|
11 January 2023 at 2:15pm
|
|
Letter to Shareholders End of Year Summary and 2023 Plans
|
20 December 2022 at 9:30am
|
|
Final Director's Interest Notice - Dr. John Lambert
|
1 December 2022 at 10:35am
|
|
ACCENT Trial Recruitment Progress
|
29 November 2022 at 2:40pm
|
|
Appendix 4D and Financial Report Half Year ended 30 Sep 22
|
18 November 2022 at 8:45am
|
|
Amplia Appoints Dr Christopher Burns CEO & Managing Director
|
7 November 2022 at 9:10am
|
|
Quarterly Activities and Cashflow Reports - Sep 2022 Qtr
|
28 October 2022 at 9:15am
|
|
Notification regarding unquoted securities - ATX
|
10 October 2022 at 8:55am
|
|
AMP886 Activity in Acute Myeloid Leukemia
|
3 October 2022 at 8:45am
|
|
AACR Conference Presentation
|
14 September 2022 at 8:30am
|
|
CEO Resignation
|
12 September 2022 at 9:59am
|
|
Notification regarding unquoted securities - ATX
|
7 September 2022 at 9:00am
|
|
Change of Director's Interest Notice - Dr. Warwick Tong
|
7 September 2022 at 8:40am
|
|
Change of Director's Interest Notice - Dr. Robert Peach
|
7 September 2022 at 8:40am
|
|
Change of Director's Interest Notice - Dr. Christopher Burns
|
7 September 2022 at 8:40am
|
|
Change of Director's Interest Notice - Mrs. Jane Bell
|
7 September 2022 at 8:40am
|
|
Change of Director's Interest Notice - Dr. John Lambert
|
6 September 2022 at 8:35am
|
|
Notification of cessation of securities - ATX
|
2 September 2022 at 5:35pm
|
|
Amplia Receives $1.8m R&D Tax Incentive
|
31 August 2022 at 9:10am
|
|
Results of Annual General Meeting
|
25 August 2022 at 12:30pm
|
|
CEO & Managing Director Presentation to AGM
|
25 August 2022 at 11:00am
|
|
Annual General Meeting - ESOP and New Constitution
|
17 August 2022 at 8:40am
|
|
Employee Security Ownership Plan
|
17 August 2022 at 8:35am
|
|
Change of Director's Interest Notice - Dr. Warwick Tong
|
4 August 2022 at 12:45pm
|
|
First Patient Recruited to ACCENT Trial in Pancreatic Cancer
|
2 August 2022 at 12:15pm
|
|
Quarterly Activities and Cashflow Reports - June 2022 Qtr
|
28 July 2022 at 11:05am
|
|
Presentation at Major Pancreatic Cancer Conference
|
25 July 2022 at 9:50am
|
|
Notice of Annual General Meeting/Proxy - YE 31 March 2022
|
22 July 2022 at 10:15am
|
|
Change of Director's Interest Notice - Dr. Chistopher Burns
|
7 July 2022 at 5:15pm
|
|
Change of Director's Interest Notice - Dr. Robert Peach
|
7 July 2022 at 5:15pm
|
|
Change of Director's Interest Notice - Dr. John Lambert
|
7 July 2022 at 5:15pm
|
|
Change of Director's Interest Notice - Dr. Warwick Tong
|
7 July 2022 at 5:05pm
|
|
Notification of cessation of securities - ATX
|
5 July 2022 at 2:35pm
|
Amplia Therapeutics